ABATA
DEAD

Serial Number

98909678

Owner

Abata Therapeutics, Inc.

Attorney

Susan Piascik Christoff

Filing Date

Dec 18, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ABATA Trademark

Serial Number: 98909678

ABATA is a trademark filed by Abata Therapeutics, Inc. on December 18, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently no longer active.

Owner Contact Info

Abata Therapeutics, Inc.

100 Forge Road, Suite 200
Watertown, MA 02472

Entity Type: 03

Trademark Details

Filing Date

December 18, 2024

Registration Date

Not Registered

Published for Opposition

July 15, 2025

Goods & Services

Custom manufacture of therapeutic drugs, namely, custom manufacture of cell and gene therapies; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for health care, for the treatment of humans suffering from diseases treated by cell therapy or gene therapy or regenerative medicine products, more specifically medicines for human use as well as medicines for experimental medical and therapeutic uses, biological products for experimental purposes, preparations for cell therapy, gene therapy, and medicines for innovative therapies

Pharmaceutical preparations for cell therapy, namely pharmaceutical preparations for T cell therapy; pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological preparations for use in medical and clinical gene therapy and cell therapy for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; pharmaceutical products for the prevention and treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; biological preparations for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory disorders, transplant complications, and immunological disorders; chemical and biochemical preparations for medical purposes, specifically, for the treatment and diagnosis of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; biochemical, namely, monoclonal antibodies for medical purposes, specifically, for the treatment and diagnosis of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 13, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 13, 2026 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 9, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 15, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 15, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 9, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 9, 2025 CNSA
ASSIGNED TO EXAMINER
Jun 4, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2025 NWOS
NEW APPLICATION ENTERED
Dec 18, 2024 NWAP